Browsing by Author "Sopta, J. (24328547800)"

People are at higher risk of cancer as they get older or have a strong family history of cancer. The potential influence of environmental and behavioral factors remains poorly understood. Earlier population and case control studies reported that upper quartile of circulating IGF-I is associated with a higher risk of developing cancer suggesting possible involvement of the growth hormone (GH)/IGF system in initiation or progression of cancer. Since GH therapy increases IGF-1 levels, there have been concerns that GH therapy in hypopituitarism might increase the risk of cancer. We report a 42-year-old female patient who presented with subacute onset of symptoms of meningitis and with the absence of fever which resulted in death 70 days after the onset of symptoms. The patient together with her younger brother was diagnosed at the age of 5 years with familial congenital hypopituitarism, due to homozygous mutation c.150delA in PROP1 gene. Due to evolving hypopituitarism, she was replaced with thyroxine (from age 5), hydrocortisone (from age 13), GH (from age 13 until 17), and sex steroids in adolescence and adulthood. Her consanguineous family has a prominent history of malignant diseases. Six close relatives had malignant disease including her late maternal aunt with breast cancer. BRCA 1 and BRCA 2 mutational analysis in the patient’s mother was negative. Histology after autopsy disclosed advanced ovarian cancer with multiple metastases to the brain, leptomeninges, lungs, heart, and adrenals. Low circulating IGF-1 did not seem to protect this patient from cancer initiation and progression in the context of strong family history of malignancies. © 2016, Springer Science+Business Media New York.

People are at higher risk of cancer as they get older or have a strong family history of cancer. The potential influence of environmental and behavioral factors remains poorly understood. Earlier population and case control studies reported that upper quartile of circulating IGF-I is associated with a higher risk of developing cancer suggesting possible involvement of the growth hormone (GH)/IGF system in initiation or progression of cancer. Since GH therapy increases IGF-1 levels, there have been concerns that GH therapy in hypopituitarism might increase the risk of cancer. We report a 42-year-old female patient who presented with subacute onset of symptoms of meningitis and with the absence of fever which resulted in death 70 days after the onset of symptoms. The patient together with her younger brother was diagnosed at the age of 5 years with familial congenital hypopituitarism, due to homozygous mutation c.150delA in PROP1 gene. Due to evolving hypopituitarism, she was replaced with thyroxine (from age 5), hydrocortisone (from age 13), GH (from age 13 until 17), and sex steroids in adolescence and adulthood. Her consanguineous family has a prominent history of malignant diseases. Six close relatives had malignant disease including her late maternal aunt with breast cancer. BRCA 1 and BRCA 2 mutational analysis in the patient’s mother was negative. Histology after autopsy disclosed advanced ovarian cancer with multiple metastases to the brain, leptomeninges, lungs, heart, and adrenals. Low circulating IGF-1 did not seem to protect this patient from cancer initiation and progression in the context of strong family history of malignancies. © 2016, Springer Science+Business Media New York.

Osteoid osteoma is a benign osteoblastic lesion of bone. Generally, osteoid osteoma doesn't have recurrences. Radical surgery offers a cure and only few cases of recurrence were published. From 1979 till 1998., 153 osteoid osteoma (OO) were introduced in Register of bone and joint tumors at the Institute of pathology, School of medicine, Belgrade. The tumor was 1,7 times more frequent in males (males 97, females 56). The lesion occured predominantly (50% or 76 cases) in the second decade of life. The youngest patient was 22 months, the oldest was 54 years old. The most common involved bone was femur (64 cases, 41,8%), but the rare locations were: index (6), polex (4), os ilei (1), os pubis (1), clavicula (1). We reviewed 2 (two) cases of OO recurrent tumors after en-bloc resection. In the first case, a 9 year-old boy, curetage was made in 1992, and OO was identified histopathologically. One year after that (1993.) the patient had identical symptoms and radical surgical therapy was performed; in the bloc-resection part of bone calcified a nidus was present. In 1998, the boy had typical clinical signs again, en-bloc tumor excision was repeated, and then the tumor which has a shape of a band (3,5×1,0cm) was histopathologically described. It was a reason to think about differential-diagnosis between osteoblastoma and OO. The second case was an 8 year-old male patient, in 1982, to whom an en-bloc resection was made, and two nidi of OO were described. One was 1,5×1,5cm, and the second was 0,3×0,3 cm. The smaller was beside the bigger one, separated each to other with a fibrovascular zone. Five years later patient had recurrent specific clinical symptoms; which led to a second en-bloc resection. Histopathologically OO was confirmed.

Chordoma is a malignant neoplasm believed to arise from notochord remnants. Its incidence is highest in the sixth decade and is generally regarded as a locally aggressive tumor with slow progression growth rate. Its metastatic incidence ranges from 5 to 40%, and it is generally believed that metastases without local recurrence of primary neoplasm are extremely rare. We report a case of a 38-year-old male patient with solitary inguinal lymph node metastasis without local recurrence of a previously surgically treated primary sacrococcygeal chordoma. © 2008 Springer-Verlag.